Welcome to our dedicated page for ARS Pharms SEC filings (Ticker: SPRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents. ARS Pharma describes itself as a commercial-stage biopharmaceutical company focused on epinephrine nasal spray products for emergency treatment of Type I allergic reactions, including anaphylaxis, and its filings help investors understand how this business is being financed, governed, and developed.
Recent Forms 8-K illustrate several important themes. Some filings report financial results and business updates for specific quarters, where ARS Pharma furnishes press releases discussing revenue from neffy, commercial launch progress, and cash resources. These items fall under “Results of Operations and Financial Condition” and “Regulation FD Disclosure,” and are incorporated by reference to attached exhibits.
Other 8-Ks describe material definitive agreements and financing arrangements, such as the senior secured term loan facility of up to $250 million with affiliates of RA Capital Management and OMERS Life Sciences. These filings outline the structure of the term loans, interest terms, collateral, covenants, and intended use of proceeds, which ARS Pharma states include funding research, development, and commercialization activities for its products, as well as general corporate purposes.
ARS Pharma also uses 8-K filings to disclose legal and intellectual property developments. For example, the company has reported receiving a Paragraph IV certification notice related to a proposed generic version of neffy 2 mg (epinephrine nasal spray) and has stated its intention to pursue patent infringement litigation to defend its listed U.S. patents.
Through Stock Titan, users can track these filings as they are posted to EDGAR and use AI-powered summaries to quickly understand the main points of each document. This includes highlighting where ARS Pharma discusses neffy’s commercialization, financing arrangements, intellectual property strategy, and other material events that may be relevant to shareholders and prospective investors.
Form 4 Overview: On 06/25/2025, ARS Pharmaceuticals, Inc. (ticker: SPRY) filed a Form 4 detailing an insider transaction by Director Brent L. Saunders.
Key Details:
- Security Granted: Stock Option (right to buy common stock)
- Quantity: 30,000 options
- Exercise Price: $17.26 per share
- Grant Date: 06/25/2025
- Expiration: 06/24/2035
- Vesting: 100% on the earlier of 25 June 2026 or the date of the company’s 2026 annual shareholder meeting (exact meeting date not yet set).
- Ownership Form: Direct (D)
No common shares were bought or sold in Table I; the filing solely reports an acquisition of derivative securities in Table II. Following the grant, Saunders beneficially owns 30,000 derivative securities (options) with no indirect holdings disclosed.
Implications for Investors: The option award is a routine director compensation action that aligns leadership incentives with shareholder value. It does not involve an open-market purchase or sale of equity and therefore has limited immediate impact on the company’s share float or insider sentiment.
ARS Pharmaceuticals, Inc. (SPRY) – Form 4 insider filing dated 06/27/2025
The filing reports a single equity incentive transaction for director Phillip M. Schneider. On 06/25/2025 Mr. Schneider received 30,000 non-qualified stock options with an exercise price of $17.26 per share, equal to the closing market price on the grant date (implied from standard practice; no discount indicated). The award vests in full on the earlier of June 25 2026 or the date of the company’s 2026 annual shareholders meeting, and will expire on 06/24/2035 if unexercised. No shares were sold or purchased in the open market, and there were no changes to Mr. Schneider’s previously held common shares.
Following the grant, Mr. Schneider beneficially owns 30,000 derivative securities (options) directly. The filing contains no additional derivative or non-derivative transactions, amendments, or 10b5-1 plan indications.
The transaction is typical annual director compensation and does not alter the company’s share count immediately; any potential dilution is deferred until exercise. Investors typically view such grants as routine governance practice that aligns board incentives with shareholder value but has minimal near-term financial impact.
ARS Pharmaceuticals (Nasdaq: SPRY) filed an 8-K disclosing the voting results of its 2025 Annual Meeting held on June 25, 2025.
- All four Class II director nominees—Richard Lowenthal, Peter Kolchinsky, Brenton Saunders and Peter Thompson—were elected to serve until the 2028 meeting.
- Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2025 with 77,258,380 votes for (≈99.5%).
No other proposals were considered and the disclosure contains no material changes to strategy, operations or financial outlook.
ARS Pharmaceuticals, Inc. (SPRY) – Form 4 insider transaction
Chief Commercial Officer Eric Karas exercised 15,000 stock options at an exercise price of $1.50 on 06/18/2025 (Code M) and simultaneously sold 15,000 common shares at $16.00 per share (Code S) under a Rule 10b5-1 trading plan adopted on 03/26/2024. Following these transactions, Karas directly holds 7,696 common shares and retains 559,588 outstanding options. No other derivative or non-derivative changes were reported.
The filing indicates routine option exercise and sale rather than an outright reduction of economic exposure, as the officer continues to hold a substantial option position. Investors may view the scheduled nature of the sale as mitigating potential negative sentiment typically associated with insider selling.